Trial met its primary objective with imeglimin observed to have a favorable safety and tolerability profile in patients with type 2 diabetes and chronic kidney disease stages 3b/4 Pharmacokinetics (PK)…
Read More
Trial met its primary objective with imeglimin observed to have a favorable safety and tolerability profile in patients with type 2 diabetes and chronic kidney disease stages 3b/4 Pharmacokinetics (PK)…